2030년까지 남미 및 중미 항체 약물 접합체 시장 예측 - 지역 분석 - 기술별(절단 가능 링커 및 비절단 가능 링커), 애플리케이션(혈액암, 유방암, 난소암, 요로상피암 및 기타) 및 유통 채널(병원) 약국, 소매 약국, 온라인 약국)
ADC 파이프라인 확대로 중남미 항체 약물 접합체 시장 촉진
다양한 바이오제약 회사들이 ADC를 개발하고 있습니다. 유망한 암 치료제로서 ADC에 대한 관심이 높아지고 있습니다. ImmunoGen, Inc와 같은 회사; NBE-Therapeutics, Seagen Inc; ADC 치료제; 머크 KGaA; 소렌토 테라퓨틱스(Sorrento Therapeutics, Inc); 신화적인 치료법; 수트로바이오파마; 피크바이오; 리제네론 파마슈티컬스; 아사나 바이오사이언스; 사노피; 나브로젠, Inc; OBI Pharma와 OBI Pharma는 서로 다른 개발 단계에 ADC를 보유하고 있습니다. 개발된 ADC의 상용 출시로 시장 규모가 크게 확대될 것으로 예상된다.
두 회사는 다양한 임상 단계와 상용화 파이프라인에서 유망한 ADC의 광범위한 목록을 개발했습니다. 파이프라인의 ADC 목록에는 Camidanlumab tesirine, ADCT-602, Zynlonta, ADCT-901, ADCT-701, ADCT-212, ADCT-601, Ladiratuzumab Vedotin, NBE-002, IMGN151, IMGN-632, IMGC 936, IMGN이 포함됩니다. -151, OBI 999, R 992, NAV-001, MYTX-011, M1231, STI-6129, 어뢰, BCMA ADC, REGN5093-M114, ASN004, TR 1801 ADC.
각사에서는 각 제품과 관련된 전임상 데이터도 공유했습니다. 예를 들어, 2023년 4월 Mythic Therapeutics는 MYTX-011(cMET 표적 ADC)에 대한 전임상 데이터를 발표했습니다. 공개된 데이터에는 광범위한 cMET+ 암을 치료하기 위한 MYTX-011의 주요 내용이 포함되어 있습니다. 마찬가지로 Araris Biotech AG는 2023년 4월 암연구협회 연례회의에서 항Nectin-4 및 항HER2 ADC에 대한 전임상 데이터를 발표했습니다. 두 ADC는 회사의 독자적인 링커 기술을 사용하여 개발되었습니다. 데이터는 직접 생체 내 연구에서 각각의 FDA 승인 ADC와 비교하여 항-Nectin-4 및 항-HER2 ADC의 향상된 항종양 활성을 입증했습니다. 따라서 혁신적인 ADC의 증가는 향후 몇 년 동안 시장 성장을 기하급수적으로 촉진할 가능성이 높습니다.
중남미 항체 약물 접합체 시장 개요
중남미의 항체 약물 접합체 시장은 브라질, 아르헨티나, 중남미 나머지 지역으로 구분됩니다. 이 지역의 시장 성장은 주로 암 검진에 대한 인식이 높아지는 데 기인합니다. 예를 들어, 브라질 장암 예방 협회(ABRAPRECI)와 대장암 예방 및 검진 프로그램은 대중의 인식을 높이기 위해 시작되었습니다. 인식 캠페인과 검진 프로그램의 성장으로 대장내시경 서비스에 대한 수요가 증가했습니다. 또한, 2020년 12월 프랑스 진단 회사인 HalioDx는 Diagnosticos da America(DASA)와 브라질에서 Immunoscore 대장암 위험 평가 테스트를 배포하는 계약을 체결했습니다. 면역점수는 종양 부위의 숙주 면역 반응을 측정하여 초기 대장암의 재발 위험을 예측하는 데 도움을 주며, 이는 치료 전략을 계획하는 데 도움이 됩니다. 계약 조건에 따라 브라질 상파울루에 본사를 둔 DASA는 테스트에 대한 독점 배포 권한을 가지며 40개 실험실 네트워크를 통해 테스트를 제공합니다. ADC는 특정 암세포를 표적으로 삼아 암세포에 독성 약물을 방출하기 때문에 국내 암 발병 사례가 늘어나 향후 시장도 성장할 것으로 예상된다. 또한, 아르헨티나의 현재 대장암 검진 계획에 따르면, 이전에 진단되지 않았던 질병의 발견으로 인해 대장암 발병률이 곧 증가할 것으로 예상됩니다. 따라서 이러한 요인은 예측 기간 동안 아르헨티나 항체 약물 접합체 시장의 발전에 기여할 가능성이 높습니다.
항체 약물 접합체 시장은 기술, 응용 프로그램, 유통 채널 및 국가를 기준으로 분류됩니다.
기술을 기반으로 중남미 항체 약물 접합체 시장 항체 약물 접합체 시장은 절단 가능한 링커와 비절단 링커로 나누어집니다. 절단 가능한 링커 부문은 2022년에 더 큰 점유율을 차지했습니다.
응용 프로그램을 기준으로 중남미 항체 약물 접합체 시장 항체 약물 접합체 시장은 혈액암, 유방암, 난소암, 요로상피암 및 다른 사람. 유방암 부문은 2022년에 가장 큰 점유율을 차지했습니다.
유통 채널을 기준으로 중남미 항체 약물 접합체 시장 항체 약물 접합체 시장은 병원 약국, 소매 약국 및 온라인 약국으로 분류됩니다. 병원 약국 부문은 2022년에 가장 큰 점유율을 차지했습니다.
국가를 기준으로 중남미 항체 약물 접합체 시장은 브라질, 아르헨티나, 중남미 나머지 지역으로 분류됩니다. 브라질은 2022년 중남미 항체 약물 접합체 시장을 장악했습니다.
Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc 및 Takeda Pharmaceutical Co Ltd가 일부입니다. 중남미 항체 약물 접합체 시장에서 활동하는 주요 기업 중 하나입니다.
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Antibody Drug Conjugates Market - Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
4.1.2 Rising Incidences of Cancer Cases
4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:
5. Antibody Drug Conjugates Market - South & Central America Market Analysis
5.1 South & Central America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
6. South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology
6.1 Overview
6.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
6.3.1 Overview
6.3.2 Cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
6.4.1 Overview
6.4.2 Non-cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application
7.1 Overview
7.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
7.3.1 Overview
7.3.2 Blood Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
7.4.1 Overview
7.4.2 Breast Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
7.5.1 Overview
7.5.2 Ovarian Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
7.6.1 Overview
7.6.2 Urothelial Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 South & Central America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Antibody Drug Conjugates Market - Country Analysis
9.1 South & Central America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 South & Central America Antibody Drug Conjugates Market Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 South & Central America: Antibody Drug Conjugates Market, by Countries, 2022 and 2030 (%)
9.1.3.1 Brazil
9.1.3.1.1 Overview
9.1.3.1.2 Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.3 Brazil: Antibody Drug Conjugates Market, by Technology
9.1.3.1.4 Brazil: Antibody Drug Conjugates Market, by Application
9.1.3.1.5 Brazil: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.2 Argentina
9.1.3.2.1 Overview
9.1.3.2.2 Argentina: Antibody Drug Conjugates Market, by Technology
9.1.3.2.3 Argentina: Antibody Drug Conjugates Market, by Application
9.1.3.2.4 Argentina: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.3 Rest of South & Central America
9.1.3.3.1 Overview
9.1.3.3.2 Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.3 Rest of South & Central America: Antibody Drug Conjugates Market, by Technology
9.1.3.3.4 Rest of South & Central America: Antibody Drug Conjugates Market, by Application
9.1.3.3.5 Rest of South & Central America: Antibody Drug Conjugates Market, by Distribution Channel
10. Antibody Drug Conjugates Market-Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Companies' Manufacturing Capacities and Capabilities
11. Company Profiles
11.1 Pfizer Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Hoffmann-La Roche Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Gilead Sciences Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 AstraZeneca Plc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Astellas Pharma Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Takeda Pharmaceutical Co Ltd
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. South & Central America Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 5. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 6. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 7. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 8. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 9. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 10. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 11. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 12. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 13. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 14. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 15. Glossary of Terms, Antibody Drug Conjugates Market
List of Figures
Figure 1. South & Central America Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. South & Central America Antibody Drug Conjugates Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. South & Central America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
Figure 6. South & Central America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. South & Central America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. South & Central America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: South & Central America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. South & Central America Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)
Figure 20. South & Central America: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 21. Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
1. Pfizer Inc
2. Hoffmann-La Roche Ltd
3. GSK Plc
4. Gilead Sciences Inc
5. AstraZeneca Plc
6. Astellas Pharma Inc
7. Takeda Pharmaceutical Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America antibody drug conjugates market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in South & Central America antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution